Adalimumab in Juvenile Idiopathic Arthritis for the treatment of uveitis (ADJUVITE study)

Trial Profile

Adalimumab in Juvenile Idiopathic Arthritis for the treatment of uveitis (ADJUVITE study)

Completed
Phase of Trial: Phase II/III

Latest Information Update: 05 Jan 2018

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Juvenile rheumatoid arthritis; Uveitis
  • Focus Therapeutic Use
  • Acronyms ADJUVITE
  • Most Recent Events

    • 23 Dec 2017 Results published in the Annals of the Rheumatic Diseases
    • 05 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top